Tags

Type your tag names separated by a space and hit enter

Efficacy of platelet-rich plasma in androgenetic alopecia patients.
J Cosmet Dermatol. 2019 Aug; 18(4):996-1001.JC

Abstract

BACKGROUND

Androgenetic alopecia (AGA), a patterned hair loss in both males and females, is a commonly occurring disease worldwide. Conventionally, no curative or satisfactory treatment is available for this condition. Therefore, in the current study, we aim to use platelet-rich plasma (PRP) as an alternative treatment option for the AGA patients.

MATERIALS AND METHODS

A total of 30 patients (20 men and 10 women) with AGA were included in the study between February 2017 and November 2017. Blood (9 cc) from each AGA patient was collected in 10 cc syringe, and PRP was isolated using commercially available kit under sterilized conditions. Isolated PRP was injected in the bald areas of scalp of AGA patients. The whole procedure was repeated after one month (two treatment sessions), and patients were followed for six months. The efficacy of PRP for restoration of hair was assessed using parameters such as hair density, terminal to vellus hair ratio, photographs, pull test, physician global assessment score, and patient global assessment score.

RESULTS

Mean hair density on first visit (before treatment) was 34.18 ± 14.36/cm2 which was increased to 50.20 ± 15.91/cm2 after 6 months of first treatment (P value <0.05). On a scale of three, mean scores of physician and patient global assessments were 1.45 ± 0.57 and 1.60 ± 0.62, respectively. Mean percentage reduction of hair pulled was 29.2% (P value <0.05) after PRP treatment. Terminal to vellus hair ratio was increased in 60% of patients after PRP therapy. No remarkable adverse effects were noted in patients.

CONCLUSION

Results showed that PRP is an effective treatment option in androgenetic alopecia as indicated by higher hair density, satisfactory physician and patient global assessment scores, and increase in terminal to vellus hair ratio.

Authors+Show Affiliations

Department of Dermatology, King Edward Medical University/ Mayo Hospital, Lahore, Pakistan.Department of Dermatology, King Edward Medical University/ Mayo Hospital, Lahore, Pakistan.Department of Biomedical Sciences, King Edward Medical University, Lahore, Pakistan.Department of Biomedical Sciences, Tissue Engineering and Regenerative Medicine Laboratory, King Edward Medical University, Lahore, Pakistan.

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

30393988

Citation

Butt, Ghazala, et al. "Efficacy of Platelet-rich Plasma in Androgenetic Alopecia Patients." Journal of Cosmetic Dermatology, vol. 18, no. 4, 2019, pp. 996-1001.
Butt G, Hussain I, Ahmed FJ, et al. Efficacy of platelet-rich plasma in androgenetic alopecia patients. J Cosmet Dermatol. 2019;18(4):996-1001.
Butt, G., Hussain, I., Ahmed, F. J., & Choudhery, M. S. (2019). Efficacy of platelet-rich plasma in androgenetic alopecia patients. Journal of Cosmetic Dermatology, 18(4), 996-1001. https://doi.org/10.1111/jocd.12810
Butt G, et al. Efficacy of Platelet-rich Plasma in Androgenetic Alopecia Patients. J Cosmet Dermatol. 2019;18(4):996-1001. PubMed PMID: 30393988.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of platelet-rich plasma in androgenetic alopecia patients. AU - Butt,Ghazala, AU - Hussain,Ijaz, AU - Ahmed,Fridoon Jawad, AU - Choudhery,Mahmood S, Y1 - 2018/11/04/ PY - 2018/05/24/received PY - 2018/08/11/revised PY - 2018/09/17/accepted PY - 2018/11/6/pubmed PY - 2019/12/18/medline PY - 2018/11/6/entrez KW - PRP KW - TrichoScan KW - androgenetic alopecia KW - pull test SP - 996 EP - 1001 JF - Journal of cosmetic dermatology JO - J Cosmet Dermatol VL - 18 IS - 4 N2 - BACKGROUND: Androgenetic alopecia (AGA), a patterned hair loss in both males and females, is a commonly occurring disease worldwide. Conventionally, no curative or satisfactory treatment is available for this condition. Therefore, in the current study, we aim to use platelet-rich plasma (PRP) as an alternative treatment option for the AGA patients. MATERIALS AND METHODS: A total of 30 patients (20 men and 10 women) with AGA were included in the study between February 2017 and November 2017. Blood (9 cc) from each AGA patient was collected in 10 cc syringe, and PRP was isolated using commercially available kit under sterilized conditions. Isolated PRP was injected in the bald areas of scalp of AGA patients. The whole procedure was repeated after one month (two treatment sessions), and patients were followed for six months. The efficacy of PRP for restoration of hair was assessed using parameters such as hair density, terminal to vellus hair ratio, photographs, pull test, physician global assessment score, and patient global assessment score. RESULTS: Mean hair density on first visit (before treatment) was 34.18 ± 14.36/cm2 which was increased to 50.20 ± 15.91/cm2 after 6 months of first treatment (P value <0.05). On a scale of three, mean scores of physician and patient global assessments were 1.45 ± 0.57 and 1.60 ± 0.62, respectively. Mean percentage reduction of hair pulled was 29.2% (P value <0.05) after PRP treatment. Terminal to vellus hair ratio was increased in 60% of patients after PRP therapy. No remarkable adverse effects were noted in patients. CONCLUSION: Results showed that PRP is an effective treatment option in androgenetic alopecia as indicated by higher hair density, satisfactory physician and patient global assessment scores, and increase in terminal to vellus hair ratio. SN - 1473-2165 UR - https://www.unboundmedicine.com/medline/citation/30393988/ DB - PRIME DP - Unbound Medicine ER -